Doramectin (Dectomax)

Doramectin is a potent macrocyclic lactone antiparasitic agent belonging to the avermectin class of endectocides, developed specifically for use in food-producing animals including cattle and swine. This broad-spectrum compound was derived through fermentation of the soil microorganism Streptomyces avermitilis and subsequently modified to enhance its efficacy and pharmacokinetic properties in target livestock species. Doramectin represents a significant advancement in veterinary parasitology, offering comprehensive protection against both internal parasites (endoparasites) and external parasites (ectoparasites) with a single treatment, thereby simplifying parasite management programs on farms and ranches. The drug is marketed primarily under the brand name Dectomax and has become an essential tool in integrated parasite management strategies for beef and dairy operations worldwide.

The mechanism of action of doramectin involves selective binding to glutamate-gated chloride channels found in invertebrate nerve and muscle cells, a target that is absent in mammals. This binding causes an influx of chloride ions, leading to hyperpolarization of the cell membrane, which results in paralysis and subsequent death of susceptible parasites. The selectivity for invertebrate chloride channels provides a wide margin of safety in mammalian hosts while delivering highly effective antiparasitic activity. Doramectin demonstrates exceptional potency against parasites, with effective concentrations measured in parts per billion, making it one of the most potent antiparasitic compounds available for livestock use.

Doramectin is commercially available in two primary formulations designed to accommodate different management practices and producer preferences. The injectable formulation contains 1% doramectin (10 mg/mL) and is administered subcutaneously at a dose of 200 micrograms per kilogram of body weight. The pour-on formulation contains 0.5% doramectin (5 mg/mL) and is applied topically along the backline of cattle at a dose of 500 micrograms per kilogram of body weight. Both formulations provide extended duration of activity due to the lipophilic nature of the compound, which results in accumulation in fat tissues and slow release over time, providing persistent protection against reinfection for several weeks following treatment.

Doramectin received FDA approval for use in cattle and swine following extensive clinical trials demonstrating safety and efficacy against a broad spectrum of economically important parasites. The drug is classified as a non-prescription product in the United States, allowing producers to purchase and administer it without veterinary oversight, although consultation with a veterinarian regarding strategic deworming programs is always recommended. The approval status and regulatory classification may vary in different countries, and producers should familiarize themselves with local regulations regarding use, withdrawal times, and any restrictions on extra-label applications. Doramectin maintains an important position in livestock parasite control programs, particularly valued for its broad spectrum of activity and convenience of single-dose administration.

Doramectin is FDA-approved for the treatment and control of a comprehensive range of internal and external parasites in beef cattle, dairy cattle (with restrictions), and swine. In cattle, the primary labeled indications include treatment of gastrointestinal roundworms encompassing multiple genera and species including Ostertagia ostertagi (including inhibited fourth-stage larvae), Haemonchus placei, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctata, C. pectinata, Oesophagostomum radiatum, Nematodirus helvetianus, Bunostomum phlebotomum, and Strongyloides papillosus. The drug also demonstrates excellent efficacy against lungworms (Dictyocaulus viviparus), eyeworms (Thelazia spp.), and tissue parasites including cattle grubs (Hypoderma bovis and H. lineatum) at various stages of development.

The ectoparasiticide activity of doramectin provides effective control of several economically significant external parasites affecting cattle production. Labeled indications include treatment of sucking lice (Linognathus vituli, Haematopinus eurysternus, and Solenopotes capillatus), biting lice (Bovicola bovis), and mange mites including both sarcoptic mange (Sarcoptes scabiei var. bovis) and psoroptic mange (Psoroptes ovis). The injectable formulation also provides effective control of horn flies (Haematobia irritans) for an extended period following treatment. This dual endectocide activity—affecting both internal and external parasites—makes doramectin particularly valuable for comprehensive parasite control programs requiring minimal handling of animals.

In swine production systems, doramectin injectable is approved for treatment and control of gastrointestinal roundworms including Ascaris suum (adult and fourth-stage larvae), Oesophagostomum species (adults and fourth-stage larvae), Strongyloides ransomi (adults), and Hyostrongylus rubidus (adults). The drug is also effective against lungworms (Metastrongylus spp.) and kidney worms (Stephanurus dentatus) in pigs. External parasite control in swine includes efficacy against mange mites (Sarcoptes scabiei var. suis) and sucking lice (Haematopinus suis), parasites that can significantly impact growth performance and feed efficiency in commercial swine operations.

Beyond direct parasiticide activity, strategic use of doramectin contributes to improved production parameters in treated animals. Effective parasite control reduces competition for nutrients, minimizes tissue damage from migrating larvae, and eliminates the metabolic burden of chronic parasitism. In grazing cattle, this translates to improved weight gains, better feed conversion efficiency, and enhanced reproductive performance. Studies have demonstrated significant economic returns from strategic deworming programs incorporating doramectin, particularly when treatments are timed to coincide with periods of maximum parasite transmission or when animals are moved to clean pastures following treatment.

While not FDA-approved for use in sheep, goats, or other minor ruminant species, doramectin may be used extra-label under the direction of a licensed veterinarian within a valid veterinarian-client-patient relationship. Such extra-label use requires extended withdrawal periods established through consultation with resources such as the Food Animal Residue Avoidance Databank (FARAD) to ensure food safety. Extra-label use in any species should only be undertaken when approved alternatives are unavailable or ineffective, and the veterinarian must take responsibility for establishing appropriate withdrawal intervals and documenting the treatment appropriately.

The standard dose of doramectin for cattle is 200 micrograms per kilogram of body weight (200 mcg/kg or 0.2 mg/kg) when administered as a subcutaneous injection. Using the 1% injectable formulation (10 mg/mL), this equates to 1 mL of product per 50 kg (110 pounds) of body weight. Accurate estimation of body weight is essential for proper dosing; underdosing may result in treatment failure and can contribute to the development of anthelmintic resistance, while overdosing increases the risk of adverse effects and is economically wasteful. The use of livestock scales or validated weight estimation methods such as weight tapes calibrated for the specific breed and production type is strongly recommended.

For the pour-on formulation in cattle, the dose is 500 micrograms per kilogram of body weight (500 mcg/kg or 0.5 mg/kg), applied topically along the midline of the back from the withers to the tailhead. Using the 0.5% pour-on solution (5 mg/mL), this equates to 1 mL per 10 kg (22 pounds) of body weight. The pour-on should be applied to dry cattle, as wet hair coats or rain within a few hours of application can reduce absorption and efficacy. Animals should not be exposed to heavy rain or allowed access to water bodies (streams, ponds) immediately following pour-on application to prevent wash-off and potential environmental contamination.

In swine, doramectin is administered exclusively by intramuscular injection in the neck region at a dose of 300 micrograms per kilogram of body weight (300 mcg/kg or 0.3 mg/kg). Using the 1% injectable solution, this corresponds to 1 mL per 33 kg (approximately 75 pounds) of body weight. The neck injection site is preferred to minimize injection site lesions that could affect valuable carcass cuts. Proper injection technique—using appropriately sized needles (16-18 gauge, 1-1.5 inch length depending on animal size), single-use needles, and aseptic procedures—is essential to reduce the risk of injection site reactions and ensure complete absorption of the drug.

Treatment timing should be strategically planned based on parasite epidemiology, production goals, and management practices. In beef cattle, common treatment times include spring turnout to pasture (to reduce pasture contamination), mid-season treatment during periods of high larval availability, and fall or housing treatment to eliminate accumulated parasite burdens before winter. For cattle grub control, treatment should occur after heel fly activity has ceased but before grubs have migrated to the esophageal or spinal regions—typically November through February in most of North America—to avoid potential complications from dying larvae in sensitive tissues. In swine, treatment is often timed to coincide with production phases such as entry into the farrowing house, movement to finishing facilities, or prior to breeding.

For optimal efficacy against inhibited Ostertagia larvae in cattle, treatment during the late fall or early winter is recommended, as this targets the largest population of inhibited larvae before they resume development in spring. When treating for mange mites, a second treatment 14 days after the initial dose may be necessary to eliminate mites that emerge from eggs laid before the first treatment. This two-dose regimen ensures all life stages are targeted and prevents rapid reinfection. Consult product labeling and veterinary guidance for specific retreatment recommendations based on the target parasite.

Withdrawal times must be strictly observed to prevent violative drug residues in meat. For cattle treated with doramectin injectable, the meat withdrawal period is 35 days. For cattle treated with the pour-on formulation, the withdrawal period is 45 days. For swine, the meat withdrawal period following injectable doramectin is 24 days. Doramectin is not approved for use in female dairy cattle of breeding age or in veal calves, as no milk withdrawal time has been established. Any extra-label use in lactating dairy cattle is prohibited under U.S. regulations. These withdrawal times may vary by country, and producers should verify local regulatory requirements before marketing animals for slaughter.

Doramectin demonstrates an excellent safety profile in cattle and swine when administered according to label directions, with adverse effects occurring infrequently at recommended doses. The wide margin of safety characteristic of macrocyclic lactones derives from the selective affinity for invertebrate glutamate-gated chloride channels, which are not present in mammalian species. Clinical studies supporting FDA approval and extensive post-market surveillance have confirmed that the incidence of adverse reactions is low, and most effects that do occur are mild and transient. However, as with all pharmaceutical products, awareness of potential side effects enables appropriate monitoring and prompt intervention when necessary.

The most commonly reported side effect following doramectin administration is transient swelling at the injection site, which may persist for several weeks following subcutaneous or intramuscular injection. This localized reaction reflects the tissue response to the drug vehicle and typically resolves without intervention. In some cases, the swelling may be accompanied by mild pain or sensitivity at the injection site, but this rarely affects animal behavior or appetite. Proper injection technique—including use of clean, sharp needles of appropriate gauge and length, injection of appropriate volumes per site, and avoiding injection into cold or previously irritated tissue—can minimize the incidence and severity of injection site reactions.

Neurological signs including ataxia (incoordination), lethargy, and mydriasis (pupil dilation) have been reported rarely following doramectin administration, typically in association with accidental overdose or administration to animals with compromised blood-brain barrier function. Young animals with incompletely developed blood-brain barriers may be more susceptible to central nervous system effects. If neurological signs occur, supportive care should be provided, as there is no specific antidote for avermectin toxicity. Most animals recover fully with supportive treatment, although recovery may take several days to weeks depending on the severity of the exposure.

In cattle treated for cattle grubs (Hypoderma larvae), host-parasite reactions can occur when large numbers of larvae die simultaneously within sensitive tissues. Larvae dying in the esophageal region can cause bloat due to swelling and inflammation of surrounding tissues, while larvae dying near the spinal column can cause hindquarter weakness, ataxia, or posterior paralysis. These reactions are not direct drug toxicity but rather inflammatory responses to dying parasites. The risk is minimized by treating cattle during the recommended treatment window (after heel fly activity ceases but before grub migration to sensitive areas) and by avoiding treatment of heavily parasitized animals during the migration period. If treatment during the migration period is unavoidable, treating smaller groups and maintaining close observation allows for prompt intervention if complications arise.

Species-specific sensitivities warrant particular attention when considering extra-label use. Certain dog breeds with ABCB1 (MDR1) gene mutations are highly susceptible to avermectin toxicity due to increased drug penetration into the central nervous system; while this is primarily a canine concern, it illustrates the importance of species-specific drug handling. In food animals, accidental ingestion by non-target species—such as dogs licking pour-on residue from treated cattle or accessing discarded injection containers—poses a potential toxicity risk. Farm dogs, particularly herding breeds, should be prevented from contacting recently treated livestock or treatment equipment. Environmental contamination through manure from treated animals can affect dung beetle populations and other beneficial invertebrates, representing an ecological consideration rather than a direct livestock health concern.

Doramectin is contraindicated for use in female dairy cattle of breeding age, as no milk discard time has been established and the drug may persist in milk at detectable levels for extended periods following treatment. This restriction applies regardless of lactation status—non-lactating dairy heifers and dry cows of breeding age are also excluded from labeled use. The regulatory prohibition reflects the zero-tolerance approach to drug residues in milk rather than evidence of harm from milk containing doramectin residues. Dairy producers requiring parasite control in replacement heifers or dry cows must select alternative products with established milk withdrawal times appropriate for their production system.

The product is not approved for use in calves intended for veal production. This restriction accounts for the extended tissue residue depletion time of doramectin combined with the relatively young slaughter age of veal calves, which does not allow sufficient time for residues to deplete below established tolerances. Veal producers should utilize alternative anthelmintic products specifically approved for use in calves destined for early slaughter, with appropriate attention to the typically shorter withdrawal times required for this production class.

Doramectin should not be administered to animals with known hypersensitivity to avermectin compounds. While true allergic reactions to doramectin are rare, animals that have demonstrated adverse reactions to doramectin or related compounds such as ivermectin, eprinomectin, moxidectin, or selamectin should not receive doramectin. Cross-reactivity among macrocyclic lactones has been documented, and animals sensitive to one compound may react to others within the class. History of previous adverse reactions should be carefully evaluated before treatment, and alternative anthelmintic classes should be selected for such animals.

Use of doramectin in severely debilitated, stressed, or diseased animals warrants careful consideration. While not an absolute contraindication, the risk-benefit ratio should be evaluated in animals experiencing concurrent disease, severe parasitism, nutritional deficiency, or other stressors. In heavily parasitized animals, the death of large numbers of parasites may release antigens that provoke inflammatory responses, potentially exacerbating the animal's condition. Severely compromised animals may also have altered drug distribution or metabolism, potentially affecting safety margins. In such cases, providing supportive care to stabilize the animal before antiparasitic treatment, or selecting treatment approaches that result in more gradual parasite death, may be appropriate. Treatment decisions for compromised animals should be made in consultation with a veterinarian who can assess individual animal status and recommend appropriate therapy.

The most clinically significant drug interaction involving doramectin in farm animal practice is the concurrent administration with other macrocyclic lactone compounds. Combining doramectin with ivermectin, moxidectin, eprinomectin, or other avermectin/milbemycin class drugs can result in additive or synergistic effects, potentially exceeding safe exposure levels and increasing the risk of toxicity. This interaction is relevant when animals are moved between properties with different deworming programs, when combination products are used without recognizing component drugs, or when multiple products are administered in error. A thorough treatment history should be obtained before administering doramectin, and adequate time should elapse between treatments with different macrocyclic lactones.

Interactions between doramectin and ionophore antibiotics represent a critical safety consideration, particularly in cattle fed ionophore-containing feeds for growth promotion or coccidiosis prevention. Ionophores including monensin, lasalocid, narasin, and salinomycin can interfere with P-glycoprotein transport mechanisms that normally limit macrocyclic lactone entry into the central nervous system. Concurrent administration may increase the risk of neurological toxicity from doramectin. While clinical problems from this interaction are uncommon at labeled doses of both drug classes, caution is warranted, and animals should be monitored following treatment. This interaction is particularly relevant in feedlot cattle receiving ionophores in feed when injectable doramectin is administered for parasite control.

P-glycoprotein inhibitors beyond ionophores may also affect doramectin disposition. Certain drugs including ketoconazole, quinidine, and cyclosporine can inhibit P-glycoprotein function, potentially increasing systemic doramectin exposure and CNS penetration. While these specific drug combinations are uncommon in routine farm animal practice, they may be relevant in intensive care situations, during treatment of concurrent conditions, or in valuable breeding stock receiving multiple medications. Consultation with a veterinarian regarding potential interactions is advisable when doramectin treatment is planned for animals receiving other medications.

Vaccine administration timing relative to doramectin treatment has been studied, with generally favorable results indicating no significant interference with immune responses. However, as a precaution, some practitioners recommend separating doramectin treatment from vaccination by at least 48 hours to avoid any potential for interaction during the initial immune response phase. This is particularly relevant for modified-live virus vaccines, which require active viral replication for immunity development. Killed vaccines and toxoids are generally less susceptible to interference. When simultaneous treatment and vaccination are necessary for practical management reasons—such as during processing of newly arrived cattle—the benefits of comprehensive health management typically outweigh theoretical interaction concerns, and both procedures may be performed concurrently.

Human safety during handling and administration of doramectin requires appropriate precautions to minimize exposure. The product is formulated in organic solvents that can enhance skin penetration, making dermal absorption a relevant exposure route. Personnel handling doramectin should wear protective gloves resistant to organic solvents, and direct skin contact with the product should be avoided. In case of accidental skin exposure, the affected area should be washed immediately with soap and water. Eye protection is recommended during use, as ocular exposure to the formulation vehicle can cause irritation. If accidental eye contact occurs, eyes should be flushed thoroughly with clean water and medical attention sought if irritation persists. Personnel with known sensitivity to avermectin compounds should avoid handling doramectin products.

Food safety and residue avoidance constitute paramount concerns in the use of any pharmaceutical in food-producing animals. Doramectin treated animals must not be slaughtered for human consumption before the established withdrawal time has elapsed—35 days for injectable in cattle, 45 days for pour-on in cattle, and 24 days for injectable in swine. Treated animals should be clearly identified through methods such as ear tags, paint marks, or written records to prevent inadvertent premature slaughter. Records of treatment dates, products used, dosages, animal identification, and calculated withdrawal dates should be maintained as part of good production practices and may be required under quality assurance programs. Producers consigning animals to sale barns or packing plants are responsible for ensuring withdrawal times have been observed.

Environmental stewardship considerations apply to doramectin use given the drug's broad-spectrum invertebrate toxicity. Residues excreted in feces of treated animals can affect dung beetle populations and other beneficial coprophagous invertebrates that play important roles in manure decomposition and nutrient cycling in pasture ecosystems. While this environmental impact does not preclude product use, it supports strategic, targeted treatment approaches rather than routine prophylactic use. Integrated parasite management programs incorporating fecal egg count monitoring to identify animals requiring treatment can reduce overall drug use while maintaining effective parasite control. Pour-on formulations may pose greater environmental risk than injectable formulations due to potential for run-off into water bodies, and application should be avoided immediately before rain or when cattle have access to surface water.

Anthelmintic resistance represents an increasing concern in livestock production, and prudent use practices are essential to preserve the efficacy of doramectin and related compounds for future use. Resistance to macrocyclic lactones has been documented in multiple nematode species affecting cattle, sheep, and other livestock. Practices that contribute to resistance development include underdosing, treating all animals regardless of parasite burden (rather than targeted selective treatment), and over-reliance on a single drug class without rotation. Fecal egg count reduction tests can assess product efficacy on individual farms, and declining efficacy should prompt review of deworming strategies in consultation with a veterinarian or parasitologist. Rotation among anthelmintic classes with different mechanisms of action, maintenance of refugia (untreated parasite populations in untreated animals or on pasture), and evidence-based treatment decisions support resistance management.

Proper use documentation serves both regulatory compliance and quality assurance objectives. Records should include the date of treatment, identity of treated animals (individual or group), product name and manufacturer, lot or serial number, dosage administered, route of administration, withdrawal date, and identity of the person administering treatment. These records support traceback capability, demonstrate compliance with quality assurance program requirements, and provide essential information for future health management decisions. Electronic record-keeping systems are increasingly available and can integrate with other herd management functions to improve record accuracy and accessibility.

Doramectin products should be stored according to label directions to maintain product stability and efficacy throughout the labeled shelf life. Both injectable and pour-on formulations should be stored at controlled room temperature, typically between 59°F and 86°F (15°C to 30°C), protected from direct sunlight and temperature extremes. Exposure to elevated temperatures can accelerate drug degradation, while freezing may cause precipitation or phase separation in the formulation. Storage areas should provide protection from temperature fluctuations that occur in uninsulated barns or storage buildings, and products should not be stored in vehicles where temperature extremes are common. Verification of storage temperature through thermometer monitoring is recommended for facilities storing pharmaceutical inventory.

Multi-dose vial handling practices significantly impact product quality and animal health outcomes. When using multi-dose containers, appropriate aseptic technique should be employed to prevent contamination. The rubber stopper should be cleaned with alcohol or disinfectant before each needle entry, and needles should be replaced frequently rather than repeatedly penetrating the stopper with the same needle. Contamination of the product with organic debris, bacteria, or other foreign material can cause injection site reactions, abscess formation, or product degradation. Multi-dose vials should be used within the timeframe specified on the label once opened, typically within several months, even if product remains. Recording the date of first opening on multi-dose containers supports appropriate use timelines.

Disposal of unused product, empty containers, and used needles must comply with applicable federal, state, and local regulations. Doramectin is toxic to fish and aquatic invertebrates, and products should not be disposed of by emptying into drains, water bodies, or areas where leaching into groundwater may occur. Empty containers should be triple-rinsed before disposal and rendered non-reusable by puncturing or crushing. Rinsate should be disposed of on land away from water sources. Used needles and syringes should be placed in designated sharps containers and disposed of through appropriate medical waste channels. Partially used or expired product should be disposed of through veterinary pharmaceutical return programs or hazardous waste collection services where available. Drug take-back programs offered by some manufacturers or veterinary distributors provide convenient options for proper disposal of expired or unwanted products.

Dosing considerations across cattle types reflect differences in body composition, metabolism, and production purpose that may influence drug distribution and residue depletion. Beef cattle breeds, particularly those with significant body condition and fat cover, may demonstrate prolonged tissue residence of lipophilic compounds like doramectin due to accumulation in adipose tissue. This extended residence supports persistent antiparasitic activity but also necessitates strict adherence to withdrawal times, as drug releases slowly from fat stores over time. Conversely, lean cattle with minimal fat cover may experience more rapid drug clearance. While label withdrawal times incorporate appropriate safety margins for the range of animals covered by the approval, awareness of these factors supports appropriate management decisions.

Dairy breeds are subject to specific use restrictions that must be carefully observed. As previously noted, doramectin is not approved for use in female dairy cattle of breeding age, regardless of lactation status. This restriction applies to Holstein, Jersey, Guernsey, Brown Swiss, Ayrshire, and other dairy breeds, as well as dual-purpose breeds when maintained in dairy production. Dairy steers raised for beef production are not subject to dairy restrictions and may be treated according to beef cattle label directions with appropriate withdrawal time observance. The distinction between dairy and beef use hinges on the intended production system and marketing channel rather than breed genetics per se.

Age and weight considerations influence treatment decisions across all species. Very young animals may have incompletely developed blood-brain barriers, potentially increasing susceptibility to neurological effects of macrocyclic lactones. While doramectin is labeled for use in cattle and swine without specific minimum age restrictions, treatment of very young animals—particularly those under one month of age—warrants careful attention to dosing accuracy and post-treatment monitoring. Accurate weight determination becomes increasingly important as animal size decreases, since the margin for dosing error narrows; a small error in estimated weight represents a larger percentage deviation from target dose in a light animal compared to a heavy animal.

Breed-specific sensitivities comparable to the well-documented collie/herding breed sensitivity in dogs have not been established in cattle or swine. However, individual animal variation in drug response does occur, and animals demonstrating adverse reactions to initial treatment should be noted and potentially excluded from future treatment with macrocyclic lactones. Some producers and veterinarians have observed anecdotal differences in drug tolerance among cattle breeds, though these have not been systematically documented in controlled studies. Until such evidence emerges, doramectin may be used in all cattle breeds according to label directions with appropriate monitoring for adverse effects. Individual animal observation following treatment remains the most practical approach to identifying unusual sensitivity.

Within the macrocyclic lactone class, several alternative products offer comparable spectrum of activity with differences in formulation, route of administration, approved species, or milk withdrawal status that may influence product selection. Ivermectin (Ivomec) was the first avermectin introduced for livestock use and remains widely used, available in injectable, pour-on, and oral formulations for various species. Eprinomectin (Eprinex) is specifically formulated for use in dairy cattle, with a zero-day milk withdrawal time that permits use in lactating animals without milk discard. Moxidectin (Cydectin, Quest) offers extended duration of activity against certain parasites and may demonstrate efficacy against some ivermectin-resistant parasite populations. Selection among these agents depends on target species, production class (dairy vs. beef), parasite spectrum present, and resistance patterns on the individual operation.

Anthelmintics from different chemical classes provide options for resistance management through class rotation and may be preferred when macrocyclic lactone resistance is suspected or confirmed. Benzimidazoles including fenbendazole (Safe-Guard, Panacur) and albendazole (Valbazen) offer broad-spectrum nematode control through a different mechanism of action (inhibition of microtubule formation). Levamisole (Prohibit, Levasole) represents the imidazothiazole class and acts through nicotinic acetylcholine receptor agonism, causing spastic paralysis of susceptible worms. These alternative classes may be used in rotation with macrocyclic lactones or in combination protocols designed to address multi-drug resistant parasite populations. Consultation with a veterinarian or parasitologist is recommended for designing effective resistance management programs.

Combination products incorporating doramectin with other active ingredients may be available in some markets. Combination of macrocyclic lactones with benzimidazoles or other anthelmintic classes in a single product provides broader coverage and can address mixed parasite populations including species with varying susceptibility to different drug classes. Additionally, products combining doramectin with flukicides such as clorsulon are available for addressing concurrent nematode and liver fluke infections. When selecting combination products, attention to the spectrum of activity, withdrawal times for all components, and approved uses for each active ingredient ensures appropriate application. The choice between combination products and sequential use of single-active products depends on the specific parasite challenges, economic considerations, and handling logistics of individual operations.